Literature DB >> 9167946

Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms.

D Wynford-Thomas1.   

Abstract

Tumours of the thyroid follicular cell are proving to be one of the most informative models for "dissecting' the molecular genetics of multi-stage human tumorigenesis. Early thyroid tumour development is closely correlated with mutation of five alternative genes, ras, ret, trk, gsp and the TSH receptor, associated with different tumour phenotypes, providing an excellent example of genotype/phenotype correlation. For two of these genes, ras and ret, there is also direct experimental evidence from gene transfer studies that they are sufficient to initiate tumorigenesis, one of very few situations where such proof of causality has been obtained for a human tumour. Much less is known of the molecular basis of malignant transformation in thyroid. However, the rare, further progression to undifferentiated (anaplastic) cancer provides a particularly clear-cut illustration of the role of the tumour-suppressor gene p53 in human cancer. Furthermore, in vitro data suggest the intriguing possibility that the anaplastic phenotype results from a combination of p53 mutation together with a spontaneous switch in differentiation programme, i.e. co-operation between a genetic and an epigenetic event.

Entities:  

Mesh:

Year:  1997        PMID: 9167946     DOI: 10.1159/000185458

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  25 in total

Review 1.  Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects.

Authors:  N J Sarlis
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

2.  Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas.

Authors:  K M La Perle; S M Jhiang; C C Capen
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  Nuclear envelope irregularity is induced by RET/PTC during interphase.

Authors:  Andrew H Fischer; Panya Taysavang; Sissy M Jhiang
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

4.  BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas.

Authors:  Paula Soares; Vítor Trovisco; Ana Sofia Rocha; Tália Feijão; Ana Paula Rebocho; Elsa Fonseca; Inês Vieira de Castro; José Cameselle-Teijeiro; Manuel Cardoso-Oliveira; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2004-04-17       Impact factor: 4.064

5.  Antisense p53 decreases production of VEGF in follicular thyroid cancer cells.

Authors:  I Hassan; A Wunderlich; E Slater; S Hoffmann; I Celik; A Zielke
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

6.  Heterochromatin protein 1 expression is reduced in human thyroid malignancy.

Authors:  Maria S Tretiakova; Sarah D Bond; David Wheeler; Alejandro Contreras; Masha Kocherginsky; Todd G Kroll; Tracy K Hale
Journal:  Lab Invest       Date:  2014-05-19       Impact factor: 5.662

7.  Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.

Authors:  Francesco Perri; Giuseppe Di Lorenzo; Giuseppina Della Vittoria Scarpati; Carlo Buonerba
Journal:  World J Clin Oncol       Date:  2011-03-10

Review 8.  Molecular pathobiology of thyroid neoplasms.

Authors:  Giovanni Tallini
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

9.  A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis.

Authors:  Rosanna Cozzolino; Gaetano Calì; Maurizio Bifulco; Paolo Laccetti
Journal:  Invest New Drugs       Date:  2009-02-03       Impact factor: 3.850

10.  Tumor size predicts malignant potential in Hürthle cell neoplasms of the thyroid.

Authors:  Rebecca S Sippel; Dina M Elaraj; Elham Khanafshar; Rasa Zarnegar; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.